clinical trial · NCT07670377
Drug-Interaction Assessment of GSK3772701 in Healthy Male and Female Participants Aged 18 to 55 Years
Malaria, FalciparumMidazolam (MDZ)GSK3772701
brief summary
This study aims to evaluate whether GSK3772701 alters the pharmacokinetics (PK) of midazolam (MDZ), a standard probe substrate for the CYP3A4 enzyme. The findings are planned to be used to determine whether GSK3772701 acts as an inducer and/or inhibitor of CYP3A4 and will help guide recommendations for safe co-administration with CYP3A4 substrates.
started
Jun 26, 2026
primary completion
Aug 24, 2026
completion
Aug 24, 2026
last updated
Jul 21, 2026
official title
A Phase 1, Open-Label Study in Healthy Participants Aged 18 to 55 Years to Investigate the CYP3A4 Interaction Potential of GSK3772701
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol